Clinical study of umbilical cord blood NK cells to improve immune function defense

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030454

Enrollment

Unknown

Registered

2020-03-02

Start date

2020-03-31

Completion date

Unknown

Last updated

2020-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IND

Interventions

Control group:Routine treatment

Experimental group:Routine treatment + cord blood NK cell

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. aged 35-90 years old; 2. Healthy or sub-healthy people; 3. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. patients with clinically diagnosed major diseases; 2. patients with serious diseases of breast, uterus and ovary; 3. pregnant women; 4. infected with HBV/HCV/HIV/TP/EB virus; 5. With history of clinically diagnosed mental illness, no experience of taking or injecting psychotropic drugs.

Design outcomes

Primary

Measure	Time frame
Number of NK cells;	—

Contacts

Public ContactWei Wei

Guangzhou reborn health management consultation co., LTD

wwei@chinacord.org+86 13729856651

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026